On Thursday, Cigna announced it will buy Express Scripts, giving ESRX shareholders a combination of cash and CI stock. The deal, expected to close before year-end, will represent the 10th buy-out of a Pawleys Growth Fund holding at a significant premium for our investors. This is a stunning accomplishment for the fund, launched in 2010, given that we typically hold a concentrated portfolio of just 20-25 different stocks. We have a systematic process which strives to identify stock of companies with little or no debt, good earnings growth, and rock-solid cash flow. We never take a position in the hopes that it will be bought-out, it just happens that our methodology has identified stocks that others deem to be very valuable. The initial Cigna offer represents a 31% premium for ESRX shareholders.
Click here to see the take-overs and performance results:
© 2018 Pawleys Investment Advisors, LLC. All rights reserved.